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ABSTRACT
Paediatric oncology is a discipline of rare diseases, defined by incidence lower than five cases per 10,000 people.  
Around 1160 new cases of childhood malignancies are diagnosed every year in Poland (2016–2017). The in-
cidence rate is about 151 children per 1 million paediatric population a year. It is calculated that one out of 
6600 children develops malignancy during one calendar year. Children with oncological diseases are treated in 
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18 centres accredited by the Polish Society of Paediatric Oncology and Haematology. Modern treatment for 
childhood cancer is based on multimodal therapy including multi-agent chemotherapy, radiotherapy, surgery, 
haematopoietic cell transplantation, and immunotherapy. All children in Poland are treated according to inter-
national therapeutic protocols in cooperation with international centres, which run as academic clinical trials. 
With this approach children with malignancy in Poland receive the same treatment as children in Western 
Europe. In this review we present current advances in diagnostics, treatment, and supportive care in paediatric 
oncology and haematology in Poland.
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INTRODUCTION
Paediatric oncology is a discipline of rare diseases, 
defined by incidence lower than five cases per 10,000 
people. Each paediatric malignancy fulfils this criterion.
Around 1160 new cases of childhood malignancies 
are diagnosed every year in Poland (2016–2017). The in-
cidence rate is about 151 children per 1 million paediat-
ric population a year (in 2017 the population of children 
under 18 years old constituted 7.65 million in Poland). It 
is calculated that 1 out of 6600 children develops malig-
nancy during one calendar year. The distribution of pae-
diatric malignancies in Poland in 2016–2017 is shown on 
Figure 1 and it remains stable over the years [1].
With over 163,000 newly diagnosed cancer cases 
reported in Poland in 2015, paediatric malignancies ac-
counted for about 0.71%. 
SYSTEM OF MEDICAL CARE
Children with oncological diseases are treated in 
18 centres accredited by the Polish Society of Paediatric 
Oncology and Haematology (Fig. 2). The system of med-
ical care in paediatric oncology and haematology in Po-
land is based on regional (provincial) centres: one centre 
per province in 12 cases; three centres in two provinces 
with the largest numbers of inhabitants (Warsaw and Up-
per Silesia); while two regions with the lowest number of 
inhabitants (Zielona Góra and Opole regions) do not re-
quire separate paediatric oncology centres due to the low 
number of newly diagnosed patients. Children from these 
two regions are treated in neighbouring regions, within 
100 km distance.
POLISH SOCIETY OF PAEDIATRIC ONCOLOGY 
AND HAEMATOLOGY
The beginnings of paediatric oncology in Poland 
date to January 2nd, 1962 when the Department of On-
cology was set up by Prof. Józef Bożek in the Institute 
of Mother and Child in Warsaw. The Polish Paediatric 
Leukaemia and Lymphoma Study Group (PPLLSG) was 
founded by prof. Jerzy Armata in 1974, and the Polish 
Paediatric Solid Tumours Study Group (PPSTG) in 1992 
by Prof. Urszula Radwańska. 
The Polish Society of Paediatric Oncology and Hae-
matology (PSPOH) was established in 1999 by prof. Jani-
na Bogusławska-Jaworska on the basis of the Polish Pae-
diatric Leukaemia and Lymphoma Study Group and the 
Polish Paediatric Solid Tumours Study Group.
Prof. Jerzy Kowalczyk was elected to be the first 
president of the Polish Society of Paediatric Oncology 
and Haematology serving two terms, 1999–2003 and 
2003–2007; Prof. Danuta Perek was the president for the 
next two terms, 2007–2011 and 2011–2016, followed by 
Prof. Tomasz Szczepański from 2016. 
FIGURE 1. The distribution of malignancy in children in Poland in 
2016–2017
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The First Congress of PSPOH was organised in 2001 in 
Bydgoszcz, followed by: Kraków (2003), Warsaw (2005), 
Białystok/Białowieża (2008), Szczecin/Międzyzdroje 
(2010), Łódź (2012), Olsztyn (2014), Zabrze/Katowice 
(2016), and Poznań (2018).
The PSPOH cooperates with a number of national 
(Polish Society of Paediatrics, Polish Society of Haema-
tology and Blood Transfusion, Polish Society of Clinical 
and Experimental Immunology, Polish Society of Paedi-
atric Surgery, Polish Transplantation Society, Polish So-
ciety of Radiation Oncology) and international (Interna-
tional Society of Paediatric Oncology; European Society 
for Paediatric Oncology, SIOPE; European Society for 
Blood and Marrow Transplantation; International BFM 
Study Group; European Intergroup for Childhood NHL; 
EWOG-MDS Study Group; Gesellschaft für Pädiatrische 
Onkologie und Hämatologie; European Network-Pae-
diatric Hodgkin’s Lymphoma Study Group; European 
Conference on Infections in Leukaemia – ECIL) scientific 
societies. Polish centres (Gdańsk, Lublin, Wrocław) are 
active members of the European Reference Network in 
Paediatric Oncology (ERNPaedCan).
Members of PSPOH are appointed for important inter-
national functions: Prof. Tomasz Szczepański was elected as 
the Main Representative of the National Paediatric Haema-
to-Oncology Societies (NaPHOS) within the SIOPE Clinical 
Research Council and SIOPE Board Member, and Prof. Jan 
Styczyński is the Chair of the Infectious Diseases Work-
ing Party (IDWP) of the European Society of Blood and 
Marrow Transplantation (EBMT); member of the Scientific 
Council and Board of EBMT, as vice-president of the ECIL.
NATIONAL CONSULTANT OF PAEDIATRIC 
ONCOLOGY AND HAEMATOLOGY
The function of the National Consultant of Paediat-
ric Oncology and Haematology was established in 1991. 
Prof. Urszula Radwańska was appointed the first National 
Consultant in 1994–1995, and thus paediatric oncology 
was separated from clinical oncology, which was chaired 
by Prof. Maciej Krzakowski. From 1995 Prof. Jerzy Kow-
alczyk was the National Consultant for over 21 years, un-
til 2017, followed by Prof. Jan Styczyński. 
Current Regional Consultants in Paediatric Oncolo-
gy and Haematology include: Prof. Tomasz Szczepań-
ski, Prof. Walentyna Balwierz, Prof. Elżbieta Drożyńska, 
Prof. Maryna Krawczuk-Rybak, Prof. Bernarda Kaza-
nowska, Prof. Michał Matysiak, Prof. Jacek Wachowiak, 
Prof. Mariusz Wysocki, Prof. Jarosław Peregud-Pogorzelski, 
Dr hab. Beata Zalewska-Szewczyk, Dr hab. Ewa Gorczyń-
ska, Dr Radosław Chaber, Dr Małgorzata Mitura-Lesiuk, 
Dr Wanda Badowska, and Dr Grażyna Karolczyk.
FIGURE 2. Oncological centres accredited by the Polish Society of Paediatric Oncology and Haematology
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ONCOLOGICAL TREATMENT
Modern treatment for childhood cancer is based on 
multimodal therapy including multi-agent chemotherapy, 
radiotherapy, surgery, haematopoietic cell transplantation 
(HCT), and immunotherapy. 
All children in Poland are treated according to interna-
tional therapeutic protocols in cooperation with interna-
tional centres, which run as academic clinical trials. With 
this approach, children with malignancy in Poland receive 
the same treatment as children in Western Europe. 
In 2017, a total of 264 children received radiothera-
py in the following malignancies: central nervous system 
(CNS) tumours (n = 95), neuroblastoma (n = 29), Ewing 
sarcoma (n = 26), acute lymphoblastic leukaemia (n = 24), 
Hodgkin lymphoma (n = 20), Wilms tumour (n = 15), 
rhabdomyosarcoma (n = 15), non-Hodgkin lymphoma 
(n = 6), osteosarcoma (n = 5), acute myeloblastic leukae-
mia (n = 3), and rare tumours (n = 13). Thirteen children 
received total body irradiation (TBI) before HCT.
Currently, HCTs are performed in six paediatric cen-
tres: Poznań (from 1989), Wrocław (from 1994), Lub-
lin (from 1998), Kraków (from 2002), Bydgoszcz (from 
2003), and Warsaw (from 2018). 
PAEDIATRIC SURGICAL ONCOLOGY 
Paediatric surgical oncology is one of the three main 
modalities of oncological therapy. The rarity of solid tu-
mours in childhood implies a centralisation of this disci-
pline in a few multidisciplinary, well equipped, and expe-
rienced centres. Such an effort has been undertaken on the 
both European (ERN) and national fields (PSPOH). Three 
to five paediatric surgical departments in Poland are con-
sidered to be the full- or nearly-full-profile, high-volume 
surgical oncology centres meeting the highest standards. 
Two of them are members of the ERNPeadCan EU system 
for paediatric onco-surgery; their responsibility includes 
expert advising and treating transferred difficult cases. 
ADVANCES IN DIAGNOSTICS AND TREATMENT
HAEMATOLOGY 
Since the early 1950s the history of Polish paediatric 
haematology began with prominent paediatricians; Prof. 
Maria Ochocka, Prof. Danuta Sońta-Jakimczyk, Prof. 
Wacława Celińska, Prof. Roma Rokicka-Milewska, Prof. 
Jerzy Armata, Prof. Urszula Radwańska, Prof. Janina Bo-
gusławska-Jaworska, and many others. At present, haema-
tology focuses on the diagnosis and treatment of all types 
of anaemias, coagulation disorders, and thrombocytopae-
nias. One of the greatest achievements is our participation 
in the European Diamond-Blackfan Anaemia Consortium 
directed by the Medical University of Warsaw, as well as 
the implementation of a program for the prevention of 
bleeding in children with haemophilia, a treatment pro-
gram for chronic thrombocytopaenia, and chelation ther-
apy. These programs were devised by the members of the 
Haematology Group of the PSPOH. A program to increas-
ing awareness of haematological disorders through a series 
of lectures, conferences, and textbooks in the field of pae-
diatric haematology was carried out.
HAEMOPHILIA: PROPHYLAXIS 
IN HAEMOPHILIA 
A major advancement in the treatment of children 
with severe haemophilia came in the form of the prophy-
laxis program initiated in 2008 in Poland [2]. For several 
months all of the patients were included in a special na-
tional program with regular infusions of factor VIII or 
factor IX concentrates. Home deliveries of concentrates 
were provided. For the last 10 years the number of factor 
VIII IU/capita increased from 3.44 to 6.68, reflecting con-
siderable achievement. In 2010 recombinant concentrates 
were introduced for children previously untreated with 
plasma-derived products. At present 40% of all children 
are currently treated with recombinants. All children who 
developed a high level of inhibitor started immune tol-
erance induction with the possibility of prophylaxis by 
regular injections of “bypassing” concentrates to prevent 
joint bleeds [3, 4]. Electronic diaries were implemented to 
register all concentrate injections during the prophylaxis 
program in 2018.
MOLECULAR TESTING IN PAEDIATRIC 
HAEMATOLOGY AND ONCOLOGY 
Molecular testing has emerged as a routine approach 
that facilitates current treatment strategies. In 2016, a cen-
tral genetic diagnostic laboratory for the whole Poland, 
called the Oncolab, was established in Łódź. Supported 
by the foundation of the Great Orchestra of Christmas 
Charity, this laboratory serves as a reference centre for 
genetic diagnosis of all known germline defects leading 
to haematological disorders, including haematological 
cancers, primary immunodeficiencies, and haemostatic 
disorders [5]. 
For instance, identification of germline defects predis-
posing to cancer, like Fanconi anaemia, Bloom syndrome, 
ataxia telangiectasia, Nijmegen syndrome (NBS), and 
many others, helps to adjust the therapy to the expected 
toxicity. Because NBS is common in the Slavic popula-
tion (the frequency of c.657_661del5 founder mutation is 
1/190), Poland became a leading country for the prepara-
tion of international recommendations for the manage-
ment of these patients [6]. Moreover, access to modern 
technology like dense SNP arrays, exome sequencing, and 
deep RNA sequencing using next-generation sequencing 
(NGS) platforms has led to a risk stratification for leukae-
mia and lymphoma, which is currently enriched by the 
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molecular minimal residual disease (MRD) measurement 
and identification of molecular targets in leukemic cells. 
All of these molecular approaches are currently available 
in Oncolab. This is especially important for paediatric pa-
tients who have resistant of relapsed disease [7]. 
FLOW CYTOMETRY TESTING IN ACUTE 
LEUKAEMIA
Flow cytometry is a basic investigation for the char-
acterisation of acute leukaemias. With the advent of mul-
ticolour cytometers, this diagnostics has become even 
more powerful. In 2006 the EuroFlow consortium “Flow 
cytometry for fast and sensitive diagnosis and follow-up 
of haematological malignancies” was established thanks 
to the European Community Framework 6 Program. 
The consortium has developed diagnostic algorithms, 
eight-colour antibody panels, uniform instrument set-
tings, as well as specialised software for standardised 
multidimensional flow cytometric immunophenotyping 
of normal, reactive, and malignant leukocytes [8, 9]. The 
Department of Paediatric Haematology and Oncology in 
Zabrze of the Medical University of Silesia in Katowice 
was one of the founding centres of the EuroFlow con-
sortium with a special contribution to acute leukaemia 
diagnostics [10–12]. The EuroFlow consortium has also 
established an inter-centre quality control program for 
the flow cytometric protocols [13]. Finally, the consor-
tium has developed standardized eight-colour flow cy-
tometry assays for highly sensitive MRD measurements 
in B-cell precursor ALL comparable to the gold standard 
of real-time quantitative polymerase chain reaction (RQ-
PCR)-based MRD detection via antigen-receptor rear-
rangements [14, 15].
ACUTE LYMPHOBLASTIC LEUKAEMIA
Treatment of childhood acute lymphoblastic leukae-
mia (ALL) in Poland was generally based on BFM back-
bone protocols since 1980. Significant progress could 
be shown in two decades in terms of treatment results; 
event-free survival (EFS) at five years was 38% in 1982 and 
almost 70% in 2002 [16, 17]. This improved outcome can 
be attributed to the optimal risk-directed therapy that in-
corporates delayed intensification with vincristine, aspar-
aginase, and dexamethasone, high-dose methotrexate, and 
early use of intrathecal therapy. In 2002 PPLLSG joined 
the ALL-IC-BFM-2002 trial, which was designed to be 
conducted in countries with inadequate skills and resourc-
es for PCR-based MRD monitoring. On the basis of the 
pioneering findings of the BFM group on measurement of 
early response to prednisone in peripheral blood on day 
8 and the percentage of bone marrow blasts on day 15, all 
patients could be stratified in risk groups by accessible and 
cheap methods [18]. A total of 1782 patients were regis-
tered and treated according to that protocol between 2002 
and 2011. The overall five-year EFS was 79% and overall 
survival (OS) was 86% for all 1782 eligible patients. The 
overall five-year EFS and five-year OS probabilities for the 
standard-risk (SR), intermediate-risk (IR), and high-risk 
(HR) group were 89% and 80%; 63% and 96%; and 87% 
and 70%, respectively. This successful trial was followed 
by the ALL IC BFM 2009 protocol started in 2012 and 
closed on 30.09.2018. Minimal residual disease measured 
by flow cytometry was added as an additional criterion for 
patient stratification. A total of 1201 children with ALL 
were treated according to ALL-IC-BFM-2009. The proba-
bility of overall five-year EFS was 90% and OS was 95% for 
the entire group of patients. The overall five-year EFS and 
five-year OS probabilities for the SR, IR, and HR groups 
is currently: 96% and 92%; 81% and 98%; and 97% and 
87%, respectively. On 1.10.2018 a new protocol AIEOP-
BFM-2017 was introduced in Poland with new stratifica-
tion approach based on MRD measured both by flow and 
molecular methods and genetic evaluation of blasts.
INFANT ACUTE LYMPHOBLASTIC LEUKAEMIA
Infant ALL is a very aggressive disease with unique 
biology characterised by the presence of MLL gene re-
arrangements and generally inferior outcome [19]. Since 
December 1999 ALL patients in Poland are treated ac-
cording to international INTERFANT protocols. The 
results of the INTERFANT’99 program has shown sig-
nificant albeit not fully satisfactory improvement in treat-
ment outcome. Overall four-year EFS and survival for all 
patients were 47% and 55.3%, respectively [20]. Howev-
er, the majority of participant groups, including PPLLSG, 
observed better outcomes with INTERFANT’99 com-
pared with historical controls both in terms of EFS as well 
as survival. The worst two-year EFS and OS concerned 
patients with congenital ALL and was approximately 20% 
[21]. Similar results were obtained for relapsed infant 
ALL (three-year OS after relapse of 24.9%) [22]. The study 
confirmed the role of HCT as a valuable treatment option 
for a subgroup of infant MLL-rearranged ALL carrying 
further poor prognostic factors [23].
ACUTE MYELOBLASTIC LEUKAEMIA
Before 1983 only about 10% children with acute my-
eloblastic leukaemia (AML) could be cured. Therapies 
based on AML-BFM protocols have led to a gradual in-
crease in the five-year EFS from about 10% before 1983 
to 52% after 2004 [24]. Since 2005 central verification of 
cell morphology, immunophenotyping, and cytogenetic 
results have been available. Since 2006 molecular studies 
have been gradually extended. The progress was achieved 
by intensification of the treatment, more accurate stratifi-
cation to risk groups, development of refined supportive 
care, and reduction of the number of toxic deaths [25]. 
Unfortunately, the rate of relapses is still high. Therefore, 
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courtesy of Prof. Dirk Reinhardt, in 2015 a new treatment 
protocol (AML-BFM 2012 Registry) with stratification 
to the risk groups based on cytogenetic and molecular 
genetics changes, as well as treatment responses, was 
introduced. Developed diagnostic panels are expanded 
using the latest molecular biology techniques such as 
nested-PCR, Sanger sequencing, and RT-qPCR to the 
currently implemented NGS analyses to adapt the avail-
able procedures to the requirements of the latest thera-
peutic protocols. Further progress in AML therapy seems 
to be possible due to cooperation between oncology cen-
tres within large international study groups. 
CHRONIC MYELOID LEUKAEMIA
Chronic myeloid leukaemia (CML) constitutes 2–3% 
of all leukaemias in paediatric patients (up to 10 new cas-
es yearly in Poland). The presence of BCR-ABL fusion is 
crucial for targeted molecular therapy with tyrosine ki-
nase inhibitors (TKI), which replaced HCT as a standard 
first-line therapy. Imatinib remains a treatment of choice 
for children with CML (according to the guidelines of the 
PPLLSG). The five-year OS rate is 96%, and the five-year 
EFS remains 81% [26]. Despite the excellent results of 
imatinib therapy, HCT is the only method for obtaining 
a definite cure of CML. HCT should be considered in pa-
tients refractory to imatinib or in children diagnosed be-
fore puberty, due to growth impairment after TKI therapy.
MYELODYSPLASTIC SYNDROMES 
Myelodysplastic syndromes and juvenile myelo-
monocytic leukaemia are diagnosed and studied with-
in international projects, providing the best therapeutic 
strategies. After 2005, patient survival in Poland in-
creased from 30% to 57%. Advances in molecular diag-
nostics help to identify rare diseases manifesting with 
bone marrow failure [27].
NON-HODGKIN LYMPHOMA
Non-Hodgkin lymphoma (NHL) is the fourth most 
common malignancy in children, comprising a heterog-
enous group of histological entities varying according to 
age at diagnosis. The prognosis for children diagnosed 
with NHL has significantly improved over the last two 
decades, with an OS rate now exceeding 80% [28]. This 
has resulted from the application of multiagent chemo-
therapy at doses adjusted to subtype and stage of NHL, as 
well as the introduction of targeted therapies (rituximab: 
anti-CD20 monoclonal antibody). Such progress could 
not have been achieved without international collabora-
tion and better understanding of the molecular biology of 
paediatric NHL [29, 30]. Challenges that remain include 
defining molecular and prognostic markers to improve 
risk stratification and developing innovative therapies.
HODGKIN LYMPHOMA
In Poland multidrug chemotherapy combined with 
involved field radiotherapy (IF-RT) was introduced for 
all stages of Hodgkin lymphoma (HL) in 1969. Initially, 
almost all patients were treated with chemotherapy and 
IF-RT. The intensity of therapy was gradually adjusted 
to the risk-factor groups, and invasive methods of stag-
ing were gradually limited. At the same time, supportive 
care was improved. The use of combined-modality ther-
apy resulted in the cure of about 90% of children [31, 
32]. However, the intensive treatment increased the risk 
of late complications, especially second malignancies. 
Therefore, treatment regimens with limited use of IF-RT 
were introduced. Thanks to Prof. Dieter Körholz, from 
June 2009 the EuroNet-PHL Protocols for classical type 
of HL are used in Polish centres. Treatment response 
assessment with PET allows the rate of patients treated 
without radiotherapy to be increased from 7% to 50% 
[33]. The use of chemotherapy as a single treatment mo-
dality in selected groups of patients did not impair the 
treatment results and decreased the risk of life-threaten-
ing complications. 
BRAIN TUMOURS 
Central nervous system (CNS) tumours are the most 
common solid tumours of childhood and are the first 
cause of cancer-related death in children younger than 
15 years of age. In Poland the introduction of unified di-
agnostic and multidisciplinary therapeutic management 
of CNS tumours in children in 1996 resulted in signifi-
cant improvement of treatment results, which at present 
are the same as in other childhood cancer centres in the 
world. At present over 70% of children with CNS tumours 
are cured. Unfortunately, brain tumour survivors expe-
rience severe late effects attributed to the disease itself, 
surgery, irradiation of CNS, and long-term toxicity of 
chemotherapy. Recent advances in molecular genetics 
have allowed us to precisely identify the tumour type and 
risk group, and stratify treatment accordingly. Identifica-
tion and better understanding of molecular mechanisms 
of tumour growth and behaviour may help to establish 
molecular targeted therapies [34–36].
NEUROBLASTOMA
In Poland 60–70 children aged 0–18 years are diag-
nosed with neuroblastoma (NBL) each year. Before 2001, 
at least four different NBL treatment protocols were used 
in Poland. Between 1991 and 2001 the five-year EFS rate 
in infants and older children with NBL was 92% and 39%, 
respectively. The five-year EFS rate in children above one 
year of age with stage 4 was 22%. To improve the results 
in the high-risk patients and to decrease the rate of ther-
apy-related side effects, since 2001 European treatment 
Pediatria Polska – Polish Journal of Paediatrics 2018; 93 (6) 457
Paediatric oncology and haematology in Poland: position paper 
protocols have been introduced systematically in Poland. 
Since 2006 cytogenetic examination and molecular stud-
ies have been gradually extended. All patients have evalu-
ated MYCN gene copy number status by interphase FISH 
technique. Each NBL tumour is screened for chromosom-
al alteration by comparative genomic hybridization array 
(performed also on formalin-fixed paraffin-embedded 
samples). Additionally, the two most common muta-
tions in ALK gene sequence in NB cells are detectable by 
Sanger sequencing from fresh as well as fixed samples. 
Improvement of five-year EFS from 22% to 40% in stage 
4 NBL was observed [37–39]. Since February 2015, chil-
dren have been treated with anty-GD2 (dinutuximab) 
immunotherapy in Kraków according to the SIOPEN 
HR-NBL protocol. Immunotherapy resulted in a further 
increase in five-year EFS in HR-NBL from 40% to 60%. 
Many issues concerning NBL treatment remain unsolved 
in Poland. 
NEPHROBLASTOMA
Nephroblastoma (Wilms’ tumour) is the most com-
mon malignant tumour of kidney origin and is the second 
(after neuroblastoma) embryonic extracranial solid tu-
mour in children. The incidence is estimated to be seven 
per 1,000,000 children under 16 years of age. In Poland, 
the preferred method of treatment is consistent with the 
recommendations of the Renal Tumour Study Group 
SIOP and coordinated within the PPSTG. The protocol 
SIOP-2001 was approved in January 2002. Our database 
currently includes over 650 children. The results of treat-
ment of children in Poland are comparable with Europe-
an results [40]. At present, we are preparing to introduce 
a new protocol, called “Umbrella”.
SOFT TISSUE SARCOMA 
Soft tissue sarcomas (STS) are a heterogeneous group 
of malignant diseases. The most common type of chil-
dren’s STS is rhabdomyosarcoma (RMS). The TNM stag-
ing system is used in clinical classification. The patients 
need multidisciplinary care, such as surgery, intense 
chemotherapy, radiotherapy, and reconstructive surgery. 
Due to unification of therapy in 17 cooperating cen-
tres (PPSTG) remarkable progress has been obtained in 
the treatment of this cancer. Enormous experience was 
gained thanks to multi-centred, international prospective 
researches (IRS, CWS, AIEOP). Currently 70% of patients 
can be cured [41–43]. In Poland the treatment is based 
on CWS strategy, starting with the CWS-91 protocol. The 
process of treatment depends on clinical and bio-molec-
ular risk factors, such as: Ki-67 expression, morphome-
try, and the presence of gene expressions: PAX3/FKHR, 
PAX7/FKHR, SYT/SSX1, SYT/SSX2, and EWS/FLI1. De-
spite the progress achieved in all cancer types, effective 
therapeutic methods, and new molecular and biological 
markers are still being sought. Introducing targeted thera-
py (INFORM cooperation) combined with chemotherapy 
gives a chance to improve effectiveness of treatment and 
might be a basis to reduce chemotherapy doses, thus re-
ducing complications related to therapy. 
BONE TUMOURS 
Primary bone tumours account for 7–8% of all ma-
lignant neoplasms in children and adolescents in Poland. 
The most common are Ewing sarcoma and osteosarcoma 
followed by chondrosarcoma and fibrosarcoma. Great 
progress has been made not only in the outcome of these 
neoplasms (in the case of localised disease the cure rate 
is about 70%) but also in the improvement in quality of 
life attributed to limb-sparing surgeries, which are sup-
ported by 3D techniques and the application of growing 
endoprosthesis [44, 45]. At present, in Poland such sur-
geries are also conducted in children even under one year 
of age. Not long ago, patients suffering from refractory 
or relapsed disease had no chance for cure. Today, with 
the introduction of new therapeutic protocols, high-dose 
therapy followed by haematopoietic stem cell rescue, and 
also by conducting more extensive surgeries along with 
new radiation techniques, has allowed an improvement in 
patient survival to 15–40%. Currently, targeted therapies 
are more often applied in the treatment of primary bone 
tumours, which not only extend the patients’ OS but also 
improve their quality of life [46]. In the near future in 
Poland a non-commercial clinical trial for children with 
Ewing sarcoma, including this type of modern treatment, 
will open.
GERM CELL TUMOURS 
Extracranial germ cell tumours (GCT) are a hetero-
geneous group of malignant tumours that arise from pri-
mordial germ cells. They account for 3–4% of all childhood 
malignancies and differ in biology, pathological type, and 
localisation. The treatment outcomes have been excellent 
since chemotherapy schedules containing cisplatin were in-
troduced in the 1970s. Long-term EFS rates range between 
73% and 90% [47]. Because of this the treatment protocols of 
GCT have been largely similar for decades. The main prob-
lems to resolve in contemporary oncology therefore are: new 
strategies to improve the results of resistant tumour treat-
ment and to minimise the late toxicities of chemotherapy 
in patients who survive. New protocols are being discussed 
and proposed in international GCT groups that specialise in 
this field [48]. International studies on the biology of GCT 
are initiated based on tumour samples collected from many 
centres [49]. In 2017 the PPSTG became affiliated as an asso-
ciate member with the largest consortium in GCT studies in 
the world – the Malignant Germ Cell International Collabo-
rative (MaGIC). It is expected that the PPSTSG will take part 
in the therapy protocols that MaGIC is developing.
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RETINOBLASTOMA 
Retinoblastoma is the most common primary intra-
ocular malignant tumour in children, and it accounts for 
2.5–3% of all childhood malignancies. In Poland approx-
imately 25–30 new cases of retinoblastoma are diagnosed 
each year. Treatment of this tumour includes systemic 
chemotherapy, focal techniques, and external beam ir-
radiation, as well as enucleation in some cases. Retino-
blastoma has survival rates of over 90%, which prompted 
the development of approaches to save eyes and visual 
function without jeopardising final outcomes. In the last 
decade intra-arterial chemotherapy has developed for 
intraocular retinoblastoma and is implemented by many 
centres in the world. This method has been adopted in 
The Children’s Memorial Health Institute in Warsaw. 
Since 2015, 61 eyes of 50 patients with intraocular reti-
noblastoma were treated with intra-arterial chemother-
apy. It allowed the preservation of 85% of the treated eye 
globes [50]. Our experience confirms that intra-arterial 
chemotherapy is safe and effective for treatment of pa-
tients with intraocular retinoblastoma, and it is available 
in Poland.
RARE TUMOURS 
Very rare paediatric tumours (VRT) are cancers oc-
curring in less than two cases per million children and 
not included in existing diagnostic-therapeutic protocols. 
Most of them belong to groups XI and XII of the Interna-
tional Childhood Cancer Classification (ICCC), compris-
ing carcinomas, melanomas, carcinoids, neuroendocrine 
neoplasms, non-germinal gonadal tumours, and many 
others. Due to their rarity, the prognosis in patients with 
VRT is uncertain because the treatment is based on case 
reports or small series of patients. In Poland, paediatric 
VRTs are registered and consulted by the Polish Paediatric 
Rare Tumour Study Group, acting since 2002 under the 
auspices of the Polish Society of Oncology and Haema-
tology. To optimise VRT therapy, Poland, Italy, Germany, 
France, and the United Kingdom in 2008 started cooper-
ation by setting up the European Cooperative Study for 
Paediatric Rare Tumours (EXPeRT) [51–53]. Numerous 
analyses form the basis for the creation of diagnostic and 
therapeutic recommendations for particular types of VRT 
in children.
HAEMATOPOIETIC CELL TRANSPLANTATION 
In Poland, between 1989–2017, the number of pae-
diatric haematopoietic stem cell transplant (HCT) cen-
tres expanded from one in 1989 to six in 2017, the total 
number of transplant beds increased from one to 45, and 
the annual number and rate of transplants increased from 
one per year (0.8/10 million) to 196 per year (268/10 mil-
lion) [54]. During the analysed time period 2702 HCTs 
were performed, including 1860 (68.8%) allogeneic 
(allo-HCT) with 142 in 2017 and 842 (31.2%) autologous 
(auto-HCT) with 54 in 2017. Among 1860 allo-HCTs, 
74.2% were performed for malignancy and 25.8% for 
non-malignant disorders. Among 842 auto-HCTs, 30.5% 
were done for haematological malignancies, while the re-
maining 69.5% were for solid tumours. Thus, it can be 
stated that in Poland the infrastructure indispensable to 
perform HCT in every child with indication for HCT 
was created during the last 30 years, and HCT became 
an important part of paediatric treatment, especially in 
paediatric oncology, haematology, and in primary immu-
nodeficiencies.
SUPPORTIVE THERAPY 
INFECTIOUS COMPLICATIONS 
Infections are the major cause of morbidity and mor-
tality in patients with cancer or undergoing HCT. In the 
study of the PSPOH, the cumulative incidence of bacte-
rial, fungal, and viral infections in oncological patients 
was 26.3%, 7.9%, and 3.5%, respectively, in Polish cen-
tres, while the cumulative risk of infection in HCT pa-
tients was respectively 1.4-fold; 3.5-fold, and 15.7-fold 
higher [55, 56]. Recent results of survival from infection 
reached 94% in fungal disease – which is a world-class 
achievement for our Society – and over 96% survival in 
multi-resistant-bacterial and viral infections. From 2014, 
a national program of antifungal prophylaxis was imple-
mented in a selected group of children with malignancy 
and/or undergoing HCT.
NUTRITION 
Nutritional status plays a significant role in the ther-
apeutic process in children with neoplastic conditions. 
Abnormal body composition, especially sarcopaenia 
observed both at diagnosis and during treatment, is an 
important factor worsening the effects of therapy in this 
group of patients. In 2016, on the initiative of PSPOH, 
a working group was established to develop nutritional 
recommendations for children with neoplastic diseases. 
In cooperation with the Polish Society for Clinical Nu-
trition of Children, nutritional workshops addressed to 
physicians and parents are carried out in Polish oncolog-
ical centres. These workshops are designed to present the 
modern principles of nutrition in patients with malignan-
cies.
PSYCHOSOCIAL SUPPORT 
During cancer treatment it is recommended not only 
to monitor somatic functioning of the patient but also 
to give well-planned bio-psychosocial support [57]. As 
a part of psychological care, the support program in-
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cludes: 1) providing parents and children with cancer 
with comprehensive information on the diagnosis and 
treatment; 2) each child with cancer should be offered 
psychological support; 3) planned psychological care 
includes diagnostic and therapeutic relations with the 
child and adolescents with cancer according to their de-
velopmental and individual needs; and 4) monitoring the 
level of adaptation to the treatment across the treatment 
course and at critical moments. The unified model of dis-
closure of cancer diagnosis was elaborated. Adaptation 
of the PedsQL™ Cancer Module (assesses quality of life) 
and PAT 2.0 (psychosocial adaptation tool) was under-
taken [58, 59]. Polish experience in the introduction of 
the planned bio-psychosocial support was noticed and 
used in guidelines entitled “European Standards of Care 
for Children with Cancer”. 
LATE EFFECTS 
In recent decades a considerable improvement in the 
treatment of childhood cancer was achieved, and more 
than 80% of children become long-term survivors; many 
of them present treatment-related adverse health com-
plications. In the Polish cohort (> 2000 registered sub-
jects) of childhood cancer survivors, we found normal 
function of all organs in 11.75% of survivors, whereas 
in 88.25% of cases one or more symptom or complaint 
suggesting organ dysfunction was observed; circulato-
ry problems were the most frequent (31.7%); > 20% of 
survivors presented complaints or abnormal function of 
urinary tract, skin, dental, or skeletal/muscular problems 
or had difficulty with chewing. Obesity or short stature 
alone was observed in 21.4%, and a variety of endocrine 
problems (short stature, obesity, thyroid dysfunction, and 
gonad toxicity) were present in 15% of females and 21% 
of males. Dysfunction of gonads as the only problem oc-
curred in 9.6% of girls and 13.4% of boys [60].
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